Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An invasive malignant tumor that originates from the surface epithelium of the ovary. It is composed of malignant epithelial cells and stroma. Representative examples include serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma, clear cell adenocarcinoma, and malignant Brenner tumor.
Biomarker and diagnostic research for malignant epithelial tumor of ovary has been reported in the published literature.
6 clinical trials registered, 4 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and medical devices. Pipeline includes 2 PHASE2, 2 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06533059](https://clinicaltrials.gov/study/NCT06533059) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:34 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors |
PHASE1 |
Alterome Therapeutics, Inc. |
ACTIVE_NOT_RECRUITING |
[NCT03686124](https://clinicaltrials.gov/study/NCT03686124) | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | PHASE1 | Immatics US, Inc. | RECRUITING |
[NCT05335993](https://clinicaltrials.gov/study/NCT05335993) | A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | PHASE2 | CanariaBio Inc. | ACTIVE_NOT_RECRUITING |
[NCT04055649](https://clinicaltrials.gov/study/NCT04055649) | ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer | PHASE2 | Ira Winer | RECRUITING |
[NCT04981119](https://clinicaltrials.gov/study/NCT04981119) | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | — | A2 Biotherapeutics Inc. | RECRUITING |
290 publications have been identified in PubMed for malignant epithelial tumor of ovary. Kisho has analyzed 144 by research type. Research spans Review / Meta-Analysis (31%), Basic Science / Preclinical (24%), and Case Report / Case Series (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 45 | 31% |
Laboratory research | 35 | 24% |
Patient case studies | 21 | 15% |
Testing and diagnosis research | 17 | 12% |
Clinical study results | 13 | 9% |
Disease patterns and progression | 10 | 7% |
New treatment approaches | 3 | 2% |
Fatima A (2026). [PMID: 41930078](https://pubmed.ncbi.nlm.nih.gov/41930078/). *Cureus*. [Diagnostic / Biomarker]
Saida T (2026). [PMID: 41047355](https://pubmed.ncbi.nlm.nih.gov/41047355/). *Magn Reson Med Sci*. [Diagnostic / Biomarker]
Mezzapesa F (2026). [PMID: 40685312](https://pubmed.ncbi.nlm.nih.gov/40685312/). *Int J Gynecol Cancer*. [Epidemiology / Natural History]
Slomovitz BM (2026). [PMID: 41385758](https://pubmed.ncbi.nlm.nih.gov/41385758/). *J Clin Oncol*. [Clinical Trial Publication]
Kaakoua M (2026). [PMID: 41909419](https://pubmed.ncbi.nlm.nih.gov/41909419/). *Cureus*. [Case Report / Case Series]
Grimes WR (2026). [PMID: 33085416](https://pubmed.ncbi.nlm.nih.gov/33085416/). *Unknown Journal*. [Basic Science / Preclinical]
Chae YK (2026). [PMID: 41672597](https://pubmed.ncbi.nlm.nih.gov/41672597/). *J Immunother Cancer*. [Clinical Trial Publication]
Scott CL (2026). [PMID: 41786760](https://pubmed.ncbi.nlm.nih.gov/41786760/). *Nat Rev Dis Primers*. [Review / Meta-Analysis]
Ramachandran T (2025). [PMID: 40655622](https://pubmed.ncbi.nlm.nih.gov/40655622/). *J Pharm Bioallied Sci*. [Case Report / Case Series]
McCluggage WG (2025). [PMID: 40739655](https://pubmed.ncbi.nlm.nih.gov/40739655/). *Int J Gynaecol Obstet*. [Review / Meta-Analysis]